# 2026年2月13日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 新斯的明作为辅助疗法在感染性休克中减弱促炎细胞因子的作用：一项随机对照试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41677407)
**期刊：** Critical care medicine
**PMID：** 41677407
**DOI：** 10.1097/CCM.0000000000007051

### 第一部分 原文与翻译

**英文原标题：** Effect of Neostigmine on Attenuation of Proinflammatory Cytokines When Given as an Adjuvant Therapy in Septic Shock: A Randomized Control Trial.

> **英文摘要：**
> OBJECTIVE: The cholinergic anti-inflammatory pathway (ChAP) is the key regulator of the dysregulated cytokine storm in sepsis, with acetylcholine acting on alpha-7 nicotinic acetylcholine receptors (α7nAChRs) to suppress excessive inflammation. The objective of this study was to evaluate whether neostigmine administration modulates the inflammatory response in sepsis by enhancing cholinergic anti-inflammatory activity.
> 
> DESIGN: A single-center, prospective, randomized, double-blinded, placebo-controlled study.
> 
> SETTING: One adult ICU at a tertiary academic medical institution.
> 
> INTERVENTION: Patients were randomized to receive neostigmine at a fixed rate of 0.2 mg/hr (2 mL/hr) or placebo. Study drug was administered for 5 days.
> 
> MEASUREMENTS AND RESULTS: The primary outcome measure was decrease in tumor necrosis factor-alpha levels, in patients treated with neostigmine adjuvant therapy vs. the standard therapy. The secondary outcomes were hemodynamic parameters, septic shock reversal, changes in procalcitonin levels, and organ failure scores. The mean tumor necrosis factor-alpha levels were significantly lower in the neostigmine group (40 ± 36 pg/mL, mean ± sd) on day 5 as compared with the control group (67 ± 43 pg/mL; p = 0.002). There was a significant reduction in Sequential Organ Failure Assessment scores from day 1 to day 5 (p < 0.001) and 28-day mortality was also lower in the neostigmine group (26%) as compared with control group (54%, p = 0.02).
> 
> CONCLUSIONS: The neostigmine infusion modulates the ChAP by potentiating the acetylcholine release leading to reduced systemic inflammation and decreased cytokine levels in septic shock patients. (Clinical Trial Registry of India number: CTRI/2023/07/ 055054).

> **中文摘要：**
> 目的：胆碱能抗炎通路（ChAP）是脓毒症中失调细胞因子风暴的关键调节器，乙酰胆碱作用于α-7烟碱型乙酰胆碱受体（α7nAChRs）以抑制过度炎症。本研究的目的是通过增强胆碱能抗炎活性，评估新斯的明给药是否能调节脓毒症的炎症反应。
> 
> 设计：一项单中心、前瞻性、随机、双盲、安慰剂对照研究。
> 
> 场所：一家三级学术医疗机构的成人重症监护室（ICU）。
> 
> 干预措施：患者被随机分配接受固定速率为0.2 mg/hr（2 mL/hr）的新斯的明或安慰剂治疗。研究药物给药持续5天。
> 
> 测量与结果：主要结局指标是接受新斯的明辅助治疗与标准治疗患者肿瘤坏死因子-α（TNF-α）水平的下降情况。次要结局指标是血流动力学参数、感染性休克逆转情况、降钙素原水平的变化以及器官功能衰竭评分。第5天新斯的明组的平均肿瘤坏死因子-α水平（40 ± 36 pg/mL，均值 ± 标准差）显著低于对照组（67 ± 43 pg/mL；p = 0.002）。序贯器官衰竭评估（SOFA）评分从第1天到第5天有显著下降（p < 0.001），且新斯的明组的28天死亡率（26%）也低于对照组（54%，p = 0.02）。
> 
> 结论：新斯的明输注通过增强乙酰胆碱的释放来调节ChAP，从而减轻感染性休克患者的全身炎症反应并降低细胞因子水平。（印度临床试验登记号：CTRI/2023/07/055054）。

### 第二部分 AI 大师评价

本研究是一项探讨神经免疫调节在脓毒症中临床应用的高质量随机对照试验。研究聚焦于通过药理学手段激活胆碱能抗炎通路，证实了低剂量持续输注新斯的明可显著降低感染性休克患者的全身促炎细胞因子水平（如TNF-α）并改善临床预后，具体表现为SOFA评分的显著下降以及28天死亡率的大幅降低（26% vs 54%）。该研究为感染性休克的免疫调节治疗提供了经济且具有创新性的临床证据，成功地将内源性抗炎机制转化为临床干预手段，但受限于单中心设计，其结论仍需在大规模多中心队列中进一步确证。

---

## 2. 在产生 OXA-484 的 ST410 型菌株中筛选出赋予头孢他啶-阿维巴坦耐药性的 CMY-219 变体

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41677308)
**期刊：** Antimicrobial agents and chemotherapy
**PMID：** 41677308
**DOI：** 10.1128/aac.01335-25

### 第一部分 原文与翻译

**英文原标题：** selection of CMY-219 conferring resistance to ceftazidime-avibactam in an OXA-484-producing  ST410.

> **英文摘要：**
> Resistance to ceftazidime-avibactam (CAZ-AVI) is a growing problem. This study describes the selection of CMY-219, a CMY-42 variant (G156D), conferring resistance to CAZ-AVI in an OXA-484-producing  ST410 after treatment. It raises concern about the risk of selection of CMY variants under CAZ-AVI exposure in ST410 and related clones, which commonly carry CMY-42, are prone to carbapenemase acquisition, and harbor modified PBP3.

> **中文摘要：**
> 头孢他啶-阿维巴坦（CAZ-AVI）耐药性是一个日益严重的问题。本研究描述了在治疗后，从一株产生 OXA-484 的 ST410 型菌株中筛选出 CMY-219（一种 CMY-42 的 G156D 变体），该变体赋予了对 CAZ-AVI 的耐药性。这引发了人们对在 CAZ-AVI 暴露下，ST410 及其相关克隆筛选出 CMY 变体风险的关注；这些克隆通常携带 CMY-42，易于获得碳青霉烯酶，并含有修饰的 PBP3。

### 第二部分 AI 大师评价

本研究通过临床案例揭示了大肠埃希菌 ST410 高风险克隆在头孢他啶-阿维巴坦（CAZ-AVI）治疗压力下的耐药演化机制。核心发现是 CMY-42 酶通过 G156D 位点突变进化为 CMY-219，从而导致对 CAZ-AVI 的获得性耐药。研究强调了携带 PBP3 修饰和 CMY-42 的特定克隆在抗生素选择压力下极易发生耐药性漂移，为临床耐药监测和精准用药提供了重要预警。

---

## 3. 一级创伤中心轻度肾功能不全至肾清除率增强的重症患者高剂量持续输注头孢吡肟相关的安全性关注：CEFTOX 研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41677262)
**期刊：** Antimicrobial agents and chemotherapy
**PMID：** 41677262
**DOI：** 10.1128/aac.01735-25

### 第一部分 原文与翻译

**英文原标题：** Safety concerns associated with high-dose continuous infusion of cefepime among critically ill patients with mild renal impairment to augmented renal clearance at a level 1 trauma center: CEFTOX study.

> **英文摘要：**
> High-dose continuous infusion of cefepime is frequently employed in ICU patients with a creatinine clearance above 60 mL/min. The CEFTOX study aimed to investigate whether this regimen could lead to cefepime overexposure and cefepime-induced neurotoxicity (CIN) in a cohort of severe trauma and brain-injured patients. This retrospective cohort study included patients from a Level 1 Trauma Center who received a continuous infusion of 6 g/day of cefepime and had a therapeutic drug monitoring (TDM) within 24-48 h of treatment initiation. They were divided into three groups based on creatinine clearance: mild renal impairment (60-90 mL/min), normal clearance (90-150 mL/min), and augmented renal clearance (ARC) (>150 mL/min). The primary outcome was cefepime overexposure. A key secondary outcome was CIN. One hundred and sixty-two critically ill patients were included: 84 with ARC, 62 with normal renal clearance, and 16 with mild renal impairment. Cefepime overexposure occurred in 72 (44.4%) patients. While 50% of patients with normal renal clearance experienced overexposure, the rate was higher in those with mild renal impairment (87.5%) and lower in those with ARC (32.1%; < 0.0001). In the ARC group, age > 33 years was a risk factor for overexposure (odds ratio [OR] 3.76; 95% CI [1.30-10.95]; = 0.01), while sepsis was a protective factor (OR 0.30; 95% CI [0.11-0.83]; = 0.02). CIN was observed in 24% of overexposed patients when TDM results were obtained ≤48 h compared to 57.4% when results were delayed >48 h ( = 0.006). These results highlight the need for early TDM and individualized dose adjustment to avoid CIN.

> **中文摘要：**
> 在肌酐清除率超过 60 mL/min 的 ICU 患者中，经常采用高剂量持续输注头孢吡肟的方案。CEFTOX 研究旨在调查该方案是否会导致一组严重创伤和脑损伤患者出现头孢吡肟暴露过量及头孢吡肟诱导的神经毒性 (CIN)。这项回顾性队列研究纳入了一家一级创伤中心的患者，这些患者接受了 6 g/天的头孢吡肟持续输注，并在治疗开始后 24-48 小时内进行了治疗药物监测 (TDM)。根据肌酐清除率将患者分为三组：轻度肾功能不全 (60-90 mL/min)、正常清除率 (90-150 mL/min) 和肾清除率增强 (ARC) (>150 mL/min)。主要结局指标是头孢吡肟暴露过量。关键的次要结局指标是 CIN。共纳入 162 名重症患者：84 名患有 ARC，62 名肾清除率正常，16 名轻度肾功能不全。72 名 (44.4%) 患者发生了头孢吡肟暴露过量。虽然 50% 的肾清除率正常患者发生了暴露过量，但在轻度肾功能不全患者中这一比例更高 (87.5%)，而在 ARC 患者中较低 (32.1%; p < 0.0001)。在 ARC 组中，年龄 > 33 岁是暴露过量的危险因素（优势比 [OR] 3.76; 95% CI [1.30-10.95]; p = 0.01），而脓毒症则是保护因素（OR 0.30; 95% CI [0.11-0.83]; p = 0.02）。当 TDM 结果在 ≤48 小时内获得时，24% 的暴露过量患者观察到 CIN，而当结果延迟 >48 小时获得时，这一比例为 57.4% (p = 0.006)。这些结果强调了早期进行 TDM 和个体化剂量调整以避免 CIN 的必要性。

### 第二部分 AI 大师评价

这项回顾性队列研究（CEFTOX）重点探讨了 ICU 重症患者在高剂量头孢吡肟持续输注模式下的药代动力学安全风险。研究发现即便在肾功能正常的患者中，暴露过量的发生率也极高，尤其是轻度肾功能受损患者面临更严峻的神经毒性风险。该研究通过对比 TDM 报告周转时间，有力地证明了早期药物监测对改善临床预后的关键作用。尽管为单中心回顾性分析，其结果为优化危重症感染患者的个体化给药策略提供了重要的实证支持。

---

## 4. 更正：预防和管理重症监护室谵妄干预措施的系统性元综述：第2部分——非药物和多组分干预。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41673871)
**期刊：** Critical care (London, England)
**PMID：** 41673871
**DOI：** 10.1186/s13054-025-05804-x

### 第一部分 原文与翻译

**英文原标题：** Correction: A systematic meta-review of interventions to prevent and manage delirium in the Intensive Care Unit: Part 2 - Non-pharmacological and multicomponent interventions.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无可用摘要。

### 第二部分 AI 大师评价

本条目是发表于《Critical Care》期刊的一篇勘误（Correction）公告，旨在修正此前关于ICU谵妄预防与管理干预措施的系统性元综述（第二部分）中的特定内容。作为学术更正文件，其核心目的是维护原始研究的准确性与科学严谨性，确保非药物及多组分干预的相关证据在临床应用中不产生歧义。该类文献虽不直接提供新研究结论，但对于引用和参考原始元综述的临床医生与研究者而言具有重要的参考价值。

---

## 5. 作者更正：一种作为细菌性肺炎潜在疗法并可缓解抗菌药物耐药性的抗菌肽。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41672983)
**期刊：** Nature communications
**PMID：** 41672983
**DOI：** 10.1038/s41467-026-69397-x

### 第一部分 原文与翻译

**英文原标题：** Author Correction: An antimicrobial peptide as a potential therapy for bacterial pneumonia that alleviates antimicrobial resistance.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

该文献是发表在《自然·通讯》上的一篇作者更正（Author Correction），针对此前关于抗菌肽治疗细菌性肺炎及其缓解耐药性潜力研究的特定内容进行了修订。由于该条目仅为更正声明且不含摘要，其核心目的是修正原研究中的数据、图表或文字描述，以维护学术出版的严谨性。这类勘误文件对于准确理解原始研究结论及确保科研数据的可重复性具有重要的参考价值。

---

## 6. 毛霉菌病

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41671483)
**期刊：** The New England journal of medicine
**PMID：** 41671483
**DOI：** 10.1056/NEJMra2412565

### 第一部分 原文与翻译

**英文原标题：** Mucormycosis.

> **英文摘要：**
> Mucormycosis is a rapidly progressive, invasive fungal infection that affects patients who are severely immunocompromised, as well as patients with diabetes and persons with immunocompetence who have major trauma. Mucormycosis manifests in several clinical forms, including sino-orbital, rhinocerebral, sinopulmonary, gastrointestinal, cutaneous, musculoskeletal, osteoarticular, and disseminated mucormycosis, as well as single-organ disease. Although mucormycosis is often lethal, early intervention reduces mortality. Successful treatment depends on early detection and staging of the disease, timely initiation of antifungal therapy, surgical resection of infected tissue, reversal of immunodeficiencies, and correction of metabolic abnormalities. Liposomal amphotericin B is the preferred agent for initial antifungal therapy, with oral triazoles as alternative agents. Research on rapid molecular diagnostic strategies, new antifungal agents, host-directed immune augmentation, antivirulence immune therapeutics, and risk-based stratification to inform management of disease may substantially improve outcomes in patients with this highly destructive mycosis.

> **中文摘要：**
> 毛霉菌病是一种进展迅速的侵袭性真菌感染，主要累及严重免疫功能受损的患者、糖尿病患者以及遭受重大创伤的免疫功能正常者。毛霉菌病表现为多种临床形式，包括鼻-眶型、鼻-脑型、鼻-肺型、胃肠型、皮肤型、肌肉骨骼型、骨关节型和播散型毛霉菌病，以及单器官受累疾病。尽管毛霉菌病通常具有致死性，但早期干预可降低死亡率。成功的治疗取决于疾病的早期发现和分期、及时启动抗真菌治疗、受感染组织的外科切除、免疫缺陷的逆转以及代谢异常的纠正。脂质体两性霉素 B 是初始抗真菌治疗的首选药物，口服三唑类药物可作为替代药物。关于快速分子诊断策略、新型抗真菌药物、宿主导向的免疫增强、抗毒力免疫治疗以及基于风险的分层管理研究，可能会显著改善这种具有高度破坏性的真菌病患者的预后。

### 第二部分 AI 大师评价

本文是一篇关于毛霉菌病的权威综述，系统性地阐述了这种高致死性侵袭性真菌感染的临床表型、诊断要点及多学科管理策略。文章强调了早期诊断、及时手术清创及脂质体两性霉素 B 治疗的组合拳效应，是当前临床处理该病的金标准。此外，该综述前瞻性地探讨了分子诊断与宿主免疫增强等前沿技术，为未来改善这种破坏性极强的感染预后提供了清晰的科研与临床指引。

---

## 7. 纵向血浆样本的多组学分析识别创伤患者的血栓炎症内型和轨迹

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41671342)
**期刊：** Science translational medicine
**PMID：** 41671342
**DOI：** 10.1126/scitranslmed.adw5223

### 第一部分 原文与翻译

**英文原标题：** Multiomic analyses of longitudinal plasma samples identify thromboinflammation endotypes and trajectories in patients with trauma.

> **英文摘要：**
> Understanding the complexity of trauma-induced thromboinflammation necessitates data-driven approaches. We hypothesized that longitudinal plasma profiling could reveal underlying differences in patients with injury who present with similar clinical characteristics but ultimately have different outcomes. Here, we performed multiomic analyses of longitudinal plasma samples from a clinical trial of patients with traumatic injury to identify molecular endotypes and trajectories that were associated with patient outcomes. The pathophysiologic states of patients with trauma were defined by the longitudinal proteomic and metabolomic plasma profiles from a diverse cohort. Then, patients were endotyped according to their longitudinal trajectories through trauma omic states, and injury patterns and outcomes were compared. We identified endotypes associated with divergent clinical outcomes despite similar injury patterns at presentation. Organ failure and time spent in the intensive care unit (ICU) were predicted with high accuracy using omic markers. Patients who presented with evidence of elevated proteasome activation, catabolism, and superoxide formation were vulnerable to heart failure, lung failure, and acute lung injury, respectively. In addition, omic markers of increased hypoxia, RBC lysis, and hydrolase activity better fit mortality and ICU time compared with injury covariates, while providing biological insight. Injury and outcome patterns persisted in a validation trauma cohort after endotype assignment at a single, early time point. These data align with the understanding that patients with trauma may experience markedly different biological responses and outcomes despite similar clinical presentations. We suggest that mapping patient trajectories through biological injury states could provide a framework for personalized patient treatment after trauma.

> **中文摘要：**
> 理解创伤诱导的血栓炎症的复杂性需要数据驱动的方法。我们假设纵向血浆分析可以揭示在受伤时表现出相似临床特征但最终结局不同的患者之间的潜在差异。在本研究中，我们对一项创伤性损伤患者临床试验的纵向血浆样本进行了多组学分析，旨在确定与患者结局相关的分子内型和轨迹。创伤患者的病理生理状态由来自多样化队列的纵向蛋白质组学和代谢组学血浆谱定义。然后，根据患者在创伤组学状态中的纵向轨迹对患者进行分型，并比较了损伤模式和结局。我们发现了尽管入院时损伤模式相似，但与不同临床结局相关的内型。使用组学标志物可以高精度预测器官衰竭和重症监护病房（ICU）停留时间。表现出蛋白酶体激活、分解代谢和超氧化物形成增加证据的患者分别易患心力衰竭、肺衰竭和急性肺损伤。此外，与损伤协变量相比，缺氧增加、红细胞裂解和水解酶活性的组学标志物更好地拟合了死亡率和 ICU 时间，同时提供了生物学见解。在单个早期时间点进行内型分配后，损伤和结局模式在验证创伤队列中依然存在。这些数据与如下理解一致：尽管临床表现相似，创伤患者可能会经历显著不同的生物学反应和结局。我们建议，通过生物损伤状态绘制患者轨迹可以为创伤后个体化治疗提供框架。

### 第二部分 AI 大师评价

本研究通过对创伤患者进行纵向多组学分析（蛋白质组学和代谢组学），成功识别了决定临床结局的分子内型和轨迹。研究揭示了即使在临床表现相似的情况下，患者仍存在显著的生物学异质性，并证明了组学标志物在预测器官衰竭、死亡率及ICU停留时间方面优于传统的临床协变量。该研究的创新之处在于利用动态轨迹数据定义病理生理状态，为创伤后的精准分诊和个体化治疗提供了一个强有力的生物学框架。

---

## 8. 腹部超声激活迷走传入神经纤维并诱导抗炎效应

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41671184)
**期刊：** Proceedings of the National Academy of Sciences of the United States of America
**PMID：** 41671184
**DOI：** 10.1073/pnas.2518969123

### 第一部分 原文与翻译

**英文原标题：** Abdominal ultrasound activates afferent vagus nerve fibers and induces anti-inflammatory effects.

> **英文摘要：**
> Abdominal ultrasound has emerged as a noninvasive modality with immunomodulatory potential. Although its anti-inflammatory effects have been demonstrated in various disease models, the underlying mechanisms remain unclear. Previous studies suggest that ultrasound promotes anti-inflammatory macrophage polarization via α7 nicotinic acetylcholine receptor (α7nAChR) signaling in the spleen. However, the upstream events initiating this response have not been elucidated. Here, we demonstrate that abdominal ultrasound activates afferent vagal fibers and suppress systemic inflammation. In a murine model of lipopolysaccharide (LPS)-induced endotoxemia, abdominal ultrasound significantly reduced plasma TNF-α levels. This anti-inflammatory effect was attenuated by subdiaphragmatic vagotomy (SDVx) or afferent vagal blockade. Electrophysiological recordings revealed increased cervical vagus nerve activity during ultrasound stimulation, which was eliminated by intraperitoneal lidocaine, confirming activation of abdominal sensory afferents. Furthermore, abdominal ultrasound induced c-Fos expression in the nucleus tractus solitarius (NTS), consistent with central activation via vagal afferent input. These findings provide direct mechanistic evidence that abdominal ultrasound stimulates afferent vagal pathways.

> **中文摘要：**
> 腹部超声已作为一种具有免疫调节潜力的非侵入性方式出现。尽管其抗炎作用已在多种疾病模型中得到证实，但其潜在机制仍不明确。先前的研究表明，超声通过脾脏中的α7烟碱型乙酰胆碱受体（α7nAChR）信号传导促进抗炎巨噬细胞极化。然而，启动这一反应的上游事件尚未阐明。在此，我们证明腹部超声可激活迷走传入纤维并抑制全身炎症。在脂多糖（LPS）诱导的内毒素血症小鼠模型中，腹部超声显著降低了血浆TNF-α水平。这种抗炎作用可被膈下迷走神经切断术（SDVx）或迷走传入阻滞所削弱。电生理记录显示，在超声刺激期间颈部迷走神经活性增加，而腹腔内注射利多卡因可消除这种活性，证实了腹部感觉传入神经的激活。此外，腹部超声诱导了孤束核（NTS）中c-Fos的表达，这与通过迷走传入输入介导的中枢激活一致。这些发现提供了直接的机制证据，表明腹部超声刺激了迷走传入通路。

### 第二部分 AI 大师评价

本研究深入探讨了腹部超声发挥免疫调节作用的神经生物学机制，明确了其通过激活腹部迷走神经传入纤维并诱导孤束核（NTS）中枢激活来抑制全身炎症的路径。研究利用电生理、神经切断及局部麻醉阻断等技术，成功识别了超声抗炎效应的上游触发事件，填补了该领域机械力信号转化为神经电信号的理论空白。这一发现为非侵入性生物电子医学手段治疗系统性炎症提供了坚实的解剖学与机制支撑。

---

速递结束，祝您工作愉快！